REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) CEO Kenneth T. Mills sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $18.19, for a total transaction of $272,850.00. Following the transaction, the chief executive officer now owns 408,035 shares in the company, valued at $7,422,156.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.
REGENXBIO Price Performance
Shares of RGNX stock opened at $17.03 on Thursday. The firm has a fifty day moving average of $20.03 and a 200-day moving average of $17.85. REGENXBIO Inc. has a 12-month low of $11.83 and a 12-month high of $28.80.
REGENXBIO (NASDAQ:RGNX – Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.16). REGENXBIO had a negative return on equity of 68.18% and a negative net margin of 291.99%. The company had revenue of $22.30 million for the quarter, compared to the consensus estimate of $34.01 million. During the same period in the prior year, the company earned ($1.38) EPS. The firm’s revenue was down 28.8% on a year-over-year basis. Research analysts anticipate that REGENXBIO Inc. will post -3.98 EPS for the current fiscal year.
Wall Street Analyst Weigh In
View Our Latest Analysis on RGNX
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in the business. BlackRock Inc. grew its position in REGENXBIO by 2.8% in the second quarter. BlackRock Inc. now owns 8,268,972 shares of the biotechnology company’s stock valued at $165,297,000 after purchasing an additional 228,182 shares in the last quarter. Vanguard Group Inc. grew its position in REGENXBIO by 1.5% in the fourth quarter. Vanguard Group Inc. now owns 4,440,838 shares of the biotechnology company’s stock valued at $79,713,000 after purchasing an additional 64,265 shares in the last quarter. JPMorgan Chase & Co. grew its position in REGENXBIO by 5.6% in the first quarter. JPMorgan Chase & Co. now owns 4,005,623 shares of the biotechnology company’s stock valued at $75,746,000 after purchasing an additional 211,146 shares in the last quarter. Finally, State Street Corp grew its position in REGENXBIO by 5.6% in the second quarter. State Street Corp now owns 2,801,494 shares of the biotechnology company’s stock valued at $69,197,000 after purchasing an additional 147,728 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.
About REGENXBIO
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Articles
- Five stocks we like better than REGENXBIO
- Profitably Trade Stocks at 52-Week Highs
- United Airlines Soars on Earnings Beat
- The How And Why of Investing in Oil Stocks
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Financial Services Stocks Investing
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for REGENXBIO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO and related companies with MarketBeat.com's FREE daily email newsletter.